Selective potentiation of gabapentin-mediated antinociception in the rat formalin test by the nicotinic acetylcholine receptor agonist ABT-594

Neuropharmacology

Volumn 59, Issue 3, 2010, Pages 208-217

  Munro, Gordon ^a   Dyhr, Helene ^a   Grunnet, Morten ^a  

^a NEUROSEARCH A S   (Denmark)

Author keywords

Analgesia; Central sensitization; Duloxetine; Hyperalgesia; Morphine; Nociception; Spontaneous pain; Synergy

Indexed keywords

5 (2 AZETIDINYLMETHOXY) 2 CHLOROPYRIDINE; DULOXETINE; GABAPENTIN; MORPHINE; NALOXONE; NICOTINIC RECEPTOR; 4 AMINOBUTYRIC ACID; 5-(2-AZETIDINYLMETHOXY)-2-CHLOROPYRIDINE; AMINE; ANALGESIC AGENT; AZETIDINE DERIVATIVE; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE; MECAMYLAMINE; NICOTINIC AGENT; NICOTINIC RECEPTOR BLOCKING AGENT; PYRIDINE DERIVATIVE; THIOPHENE DERIVATIVE;

ANALGESIC ACTIVITY; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; DRUG SELECTIVITY; EXPERIMENTAL TEST; FLINCHING BEHAVIOR; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; RAT; ANIMAL; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; EXPLORATORY BEHAVIOR; MALE; METABOLISM; PAIN; PAIN MEASUREMENT; SPRAGUE DAWLEY RAT;

AMINES; ANALGESICS; ANIMALS; AZETIDINES; CYCLOHEXANECARBOXYLIC ACIDS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; EXPLORATORY BEHAVIOR; GAMMA-AMINOBUTYRIC ACID; MALE; MECAMYLAMINE; MORPHINE; NICOTINIC AGONISTS; NICOTINIC ANTAGONISTS; PAIN; PAIN MEASUREMENT; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; THIOPHENES;

EID: 77954243474     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2010.05.010     Document Type: Article

References (51)

1. Abbott F.V., Franklin K.B., Westbrook R.F. The formalin test: scoring properties of the first and second phases of the pain response in rats. Pain 1995, 60:91-102.
2. Bannon A.W., Decker M.W., Curzon P., Buckley M.J., Kim D.J., Radek R.J., Lynch J.K., Wasicak J.T., Lin N.H., Arnold W.H., Holladay M.W., Williams M., Arneric S.P. ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors: II. In vivo characterization. Journal of Pharmacology & Experimental Therapeutics 1998, 285:787-794.
3. Bannon A.W., Decker M.W., Holladay M.W., Curzon P., Donnelly-Roberts D., Puttfarcken P.S., Bitner R.S., Diaz A., Dickenson A.H., Porsolt R.D., Williams M., Arneric S.P. Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors. Science 1998, 279:77-81.
4. Bitner R.S., Nikkel A.L., Curzon P., Arneric S.P., Bannon A.W., Decker M.W. Role of the nucleus raphe magnus in antinociception produced by ABT-594: immediate early gene responses possibly linked to neuronal nicotinic acetylcholine receptors on serotonergic neurons. Journal of Neuroscience 1998, 18:5426-5432.
5. Blackburn-Munro G. Pain-like behaviours in animals - how human are they?. Trends in Pharmacological Sciences 2004, 25:299-305.
6. Blackburn-Munro G., Erichsen H.K. Antiepileptics and the treatment of neuropathic pain: evidence from animal models. Current Pharmaceutical Design 2005, 11:2961-2976.
7. Bomholt S.F., Mikkelsen J.D., Blackburn-Munro G. Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuropathic pain. Neuropharmacology 2005, 48:252-263.
8. Bouaziz H., Tong C., Yoon Y., Hood D.D., Eisenach J.C. Intravenous opioids stimulate norepinephrine and acetylcholine release in spinal cord dorsal horn. Systematic studies in sheep and an observation in a human. Anesthesiology 1996, 84:143-154.
9. Boyce S., Webb J.K., Shepheard S.L., Russell M.G., Hill R.G., Rupniak N.M. Analgesic and toxic effects of ABT-594 resemble epibatidine and nicotine in rats. Pain 2000, 85:443-450.
10. Bymaster F.P., Dreshfield-Ahmad L.J., Threlkeld P.G., Shaw J.L., Thompson L., Nelson D.L., Hemrick-Luecke S.K., Wong D.T. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 2001, 25:871-880.
11. Coderre T.J., Katz J., Vaccarino A.L., Melzack R. Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence. Pain 1993, 52:259-285.
12. Donnelly-Roberts D.L., Puttfarcken P.S., Kuntzweiler T.A., Briggs C.A., Anderson D.J., Campbell J.E., Piattoni-Kaplan M., McKenna D.G., Wasicak J.T., Holladay M.W., Williams M., Arneric S.P. ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors: I. In vitro characterization. Journal of Pharmacology & Experimental Therapeutics 1998, 285:777-786.
13. Dubuisson D., Dennis S.G. The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. Pain 1977, 4:161-174.
14. Egan T.M., North R.A. Actions of acetylcholine and nicotine on rat locus coeruleus neurons in vitro. Neuroscience 1986, 19:565-571.
15. Erichsen H.K., Hao J.X., Xu X.J., Blackburn-Munro G. Comparative actions of the opioid analgesics morphine, methadone and codeine in rat models of peripheral and central neuropathic pain. Pain 2005, 116:347-358.
16. Finnerup N.B., Jensen T.S. Mechanisms of disease: mechanism-based classification of neuropathic pain-a critical analysis. Nature Clinical Practice Neurology 2006, 2:107-115.
17. Franklin K.B., Abbott F.V. Pentobarbital, diazepam, and ethanol abolish the interphase diminution of pain in the formalin test: evidence for pain modulation by GABAA receptors. Pharmacology Biochemistry & Behaviour 1993, 46:661-666.
18. Gage H.D., Gage J.C., Tobin J.R., Chiari A., Tong C., Xu Z., Mach R.H., Efange S.M., Ehrenkaufer R.L., Eisenach J.C. Morphine-induced spinal cholinergic activation: in vivo imaging with positron emission tomography. Pain 2001, 91:139-145.
19. Gee N.S., Brown J.P., Dissanayake V.U., Offord J., Thurlow R., Woodruff G.N. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. Journal of Biological Chemistry 1996, 271:5768-5876.
20. Gilron I., Max M.B. Combination pharmacotherapy for neuropathic pain: current evidence and future directions. Expert Reviews in Neurotherapeutics 2005, 5:823-830.
21. Gogas K.R., Cho H.J., Botchkina G.I., Levine J.D., Basbaum A.I. Inhibition of noxious stimulus-evoked pain behaviors and neuronal fos-like immunoreactivity in the spinal cord of the rat by supraspinal morphine. Pain 1996, 65:9-15.
22. Hayashida K., Obata H., Nakajima K., Eisenach J.C. Gabapentin acts within the locus coeruleus to alleviate neuropathic pain. Anesthesiology 2008, 109:1077-1084.
23. Hayashida K., Parker R., Eisenach J.C. Oral gabapentin activates spinal cholinergic circuits to reduce hypersensitivity after peripheral nerve injury and interacts synergistically with oral donepezil. Anesthesiology 2007, 106:1213-1219.
24. Henry J.L., Yashpal K., Pitcher G.M., Coderre T.J. Physiological evidence that the interphase in the formalin test is due to active inhibition. Pain 1999, 82:57-63.
25. Hwang J.H., Yaksh T.L. Effect of subarachnoid gabapentin on tactile-evoked allodynia in a surgically induced neuropathic pain model in the rat. Regional Anesthesia 1997, 22:249-256.
26. Iyengar S., Webster A.A., Hemrick-Luecke S.K., Xu J.Y., Simmons R.M. Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats. Journal of Pharmacology & Experimental Therapeutics 2004, 311:576-584.
27. Joshi S.K., Mikusa J.P., Weaver B., Honore P. Morphine and ABT-594 (a nicotinic acetylcholine agonist) exert centrally mediated antinociception in the rat cyclophosphamide cystitis model of visceral pain. Journal of Pain 2008, 9:146-156.
28. Kasamo K., Blier P., De Montigny C. Blockade of the serotonin and norepinephrine uptake processes by duloxetine: in vitro and in vivo studies in the rat brain. Journal of Pharmacology & Experimental Therapeutics 1996, 277:278-286.
29. Kesingland A.C., Gentry C.T., Panesar M.S., Bowes M.A., Vernier J.M., Cube R., Walker K., Urban L. Analgesic profile of the nicotinic acetylcholine receptor agonists, (+)-epibatidine +and ABT-594 in models of persistent inflammatory and neuropathic pain. Pain 2000, 86:113-118.
30. Klimscha W., Tong C., Eisenach J.C. Intrathecal alpha 2-adrenergic agonists stimulate acetylcholine and norepinephrine release from the spinal cord dorsal horn in sheep. An in vivo microdialysis study. Anesthesiology 1997, 87:110-116.
31. Leventhal L., Smith V., Hornby G., Andree T.H., Brandt M.R., Rogers K.E. Differential and synergistic effects of selective norepinephrine and serotonin reuptake inhibitors in rodent models of pain. Journal of Pharmacology & Experimental Therapeutics 2007, 320:1178-1185.
32. Lynch J.J., Wade C.L., Mikusa J.P., Decker M.W., Honore P. ABT-594 (a nicotinic acetylcholine agonist): anti-allodynia in a rat chemotherapy-induced pain model. European Journal of Pharmacology 2005, 509:43-48.
33. McNamara C.R., Mandel-Brehm J., Bautista D.M., Siemens J., Deranian K.L., Zhao M., Hayward N.J., Chong J.A., Julius D., Moran M.M., Fanger C.M. TRPA1 mediates formalin-induced pain. Proceedings of the National Academy of Sciences U.S.A 2007, 104:13525-13530.
34. Munro G. Dopamine D(1) and D(2) receptor agonism enhances antinociception mediated by the serotonin and noradrenaline reuptake inhibitor duloxetine in the rat formalin test. European Journal of Pharmacology 2007, 57:66-74.
35. Munro G. Pharmacological assessment of the rat formalin test utilizing the clinically used analgesic drugs gabapentin, lamotrigine, morphine, duloxetine, tramadol and ibuprofen: influence of low and high formalin concentrations. European Journal of Pharmacology 2009, 605:95-102.
36. Muneoka K., Shirayama Y., Takigawa M., Shioda S. Brain region-specific effects of short-term treatment with duloxetine, venlafaxine, milnacipran and sertraline on monoamine metabolism in rats. Neurochemical Research 2009, 34:542-555.
37. Munro G., Erichsen H.K., Mirza N.R. Pharmacological comparison of anticonvulsant drugs in animal models of persistent pain and anxiety. Neuropharmacology 2007, 53:609-618.
38. Ortega-Varela L.F., Herrera J.E., Caram-Salas N.L., Rocha-González H.I., Granados-Soto V. Isobolographic analyses of the gabapentin-metamizol combination after local peripheral, intrathecal and oral administration in the rat. Pharmacology 2007, 79:214-222.
39. Pedersen L.H., Blackburn-Munro G. Pharmacological characterisation of place escape/avoidance behaviour in the rat chronic constriction injury model of neuropathic pain. Psychopharmacology 2006, 185:208-217.
40. Pezet S., Marchand F., DMello R., Grist J., Clark A.K., Malcangio M., Dickenson A.H., Williams R.J., McMahon S.B. Phosphatidylinositol 3-kinase is a key mediator of central sensitization in painful inflammatory conditions. Journal of Neuroscience 2008, 28:4261-4270.
41. Radulovic L.L., Turck D., von Hodenberg A., Vollmer K.O., McNally W.P., DeHart P.D., Hanson B.J., Bockbrader H.N., Chang T. Disposition of gabapentin (neurontin) in mice, rats, dogs, and monkeys. Drug Metabolism & Disposition 1995, 23:441-448.
42. Rowbotham M.C., Duan W.R., Thomas J., Nothaft W., Backonja M.M. A randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of ABT-594 in patients with diabetic peripheral neuropathic pain. Pain 2009, 146:245-252.
43. Rueter L.E., Kohlhaas K.L., Curzon P., Surowy C.S., Meyer M.D. Peripheral and central sites of action for A-85380 in the spinal nerve ligation nmodel of neuropathic pain. Pain 2003, 103:269-276.
44. Tallarida R.J. Perspectives in pharmacology: an overviewof drug combination analysis with isobolograms. Journal of Pharmacology & Experimental Therapeutics 2006, 319:1-7.
45. Tallarida R.J., Porreca F., Cowan A. Statistical analysis of drug-drug and site-site interactions with isobolograms. Life Sciences 1989, 45:947-961.
46. Tallarida R.J., Stone D.J., Raffa R.B. Efficient designs for studying synergistic drug combinations. Life Sciences 1997, 61:PL 417-PL 425.
47. Tanabe M., Takasu K., Kasuya N., Shimizu S., Honda M., Ono H. Role of descending noradrenergic system and spinal alpha2-adrenergic receptors in the effects of gabapentin on thermal and mechanical nociception after partial nerve injury in the mouse. British Journal of Pharmacology 2005, 144:703-714.
48. Yaksh T.L., Ozaki G., McCumber D., Rathbun M., Svensson C., Malkmus S., Yaksh M.C. An automated flinch detecting system for use in the formalin nociceptive bioassay. Journal of Applied Physiology 2001, 90:2386-2402.
49. Young T., Wittenauer S., Parker R., Vincler M. Peripheral nerve injury alters spinal nicotinic acetylcholine receptor pharmacology. European Journal of Pharmacology 2008, 590:163-169.
50. Zarrindast M.R., Baghdadi B., Sahebgharani M. Potentiation of imipramine-induced antinociception by nicotine in the formalin test. European Neuropsychopharmacology 2004, 14:71-76.
51. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983, 16:109-110.